Get the latest tech news
FTC challenges 'junk' patents held by 10 drugmakers, incl Novo Nordisk's Ozempic
The agency sent letters to Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, among others.
"By filing bogus patent listings, pharma companies block competition and inflate the cost of prescription drugs, forcing Americans to pay sky-high prices for medicines they rely on," FTC Chair Lina Khan said in a release. The FTC has argued that drugmakers are needlessly listing dozens of extra patents for branded medications to keep their drug prices high and stall generic competitors from entering the U.S. market. "We applaud the FTC's work with FDA to crack down on Big Pharma's patent games and lower costs for prescription drugs—including weight loss and diabetes drugs," Jon Donenberg, National Economic Council deputy director, said in a statement to CNBC.
Or read this on Hacker News
